2 news items
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
proceeds.R&D Expenses: Research and development expenses for the first quarter of 2024 were $2.4
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
a warrant inducement transaction resulting in $5.0 million in gross proceeds.R&D Expenses
- Prev
- 1
- Next